<DOC>
	<DOCNO>NCT00349934</DOCNO>
	<brief_summary>Open label , non-randomized , fixed dose-escalation phase I study , perform ambulatory setting patient receive first line chemotherapy metastatic breast carcinoma standard 6 cycle weekly paclitaxel ( 80 mg/m² D1 , D8 D15 4-week cycle ) . Three IMP321 dos ( 0.25 , 1.25 6.25 mg ) test give D2 D16 4-week cycle , 6 course .</brief_summary>
	<brief_title>IMP321 Plus First-line Paclitaxel Metastatic Breast Carcinoma</brief_title>
	<detailed_description>This study open label , non-randomized , fixed dose-escalation phase I study , perform ambulatory setting patient receive first line chemotherapy metastatic breast carcinoma standard 6 cycle paclitaxel ( 80 mg/m² D1 , D8 D15 every 4-week cycle ) . Twenty mg i.v . dexamethasone give first cycle paclitaxel infusion . Corticosteroids administer first chemotherapy cycle first 3 i.v . infusion paclitaxel well tolerate . Three IMP321 dose level ( 0.25 , 1.25 6.25 mg ) evaluate three cohort lesat 8 patient . At give dose level patient administer one dose every two week total 24 week ( 12 injection total ) , separate 13-day interval free IMP321 administration . The study drug give subcutaneous injection : - Cohort A : 0.25 mg s.c. - Cohort B : 1.25 mg s.c. - Cohort C : 6.25 mg s.c . The repeated single dos administer D2 D16 4-week cycle , day follow chemotherapy . After screen perform Week -2 Day 1 , patient enter main study period . Upon complete 6 cycle IMP321 treatment Week 23 , ambulatory 'post-study ' examination ( Week 25 ) . Cohort B undertaken safety tolerability result Cohort A satisfactory ; investigator take decision involve last 8 patient study 6th administration ( Week 13 assessment ) fifth patient Cohort A . All cohort follow schedule Standard clinical laboratory safety examination , CT scan pharmacodynamic ( PD ) blood test perform . A complete examination carry Week 13 ( 6th drug dosing ) Week 25 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients stage IV breast adenocarcinoma , histologically proven biopsy primary tumor and/or metastasis . Female pregnant ( negative pregnancy test ) male . Fertile patient must use effective contraception 3 month drug administration . 18 year . ECOG performance status 01 . Expected survival longer three month . Resolution toxicity prior therapy grade &lt; 2 ( except alopecia ) . With without prior adjuvant neoadjuvant chemotherapy ( authorize ) . With without hormone therapy adjuvant and/or advance setting ( authorize ) . Evidence measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) . Biphosphonate therapy must start least 4 week prior first dose study drug . Asthma chronic obstructive pulmonary disease allow provided daily systemic corticosteroid therapy require . Total white cell count ≥ 3.109/L . Platelet count ≥ 100.109/L . Hemoglobin &gt; 9 g/dL &gt; 5.58 mmol/L . Serum creatinine &lt; 160 µmol/L . Total bilirubin &lt; 20 mmol/L , except familial cholemia ( Gilbert 's disease ) . Serum ASAT ALAT &lt; 3 time upper limit normal &lt; 5 time upper limit normal liver metastasis present . Able give write informed consent comply protocol . Prior chemotherapy metastatic breast adenocarcinoma . Diseasefree interval &lt; 12 month last dose adjuvant chemotherapy . Prior highdose chemotherapy require hematopoietic stem cell rescue . Inflammatory carcinoma . Systemic chemotherapy , hormone endocrine therapy give breast cancer therapy within 30 day prior first dose study drug . Any investigational drug within 30 day prior first dose study drug . Candidate treatment trastuzumab administration trastuzumab within 30 day prior first dose study drug . Known cerebral leptomeningeal metastasis . Pregnancy breast feed . Serious intercurrent infection within 30 day prior first dose study drug . Motor sensory peripheral neuropathy ≥ 2 accord National Cancer Institute criterion . Congestive heart failure . Active acute chronic infection . Active autoimmune disease require immunosuppressive therapy . Known HIV positivity . Life threaten illness unrelated cancer . Previous malignancy within last two year breast carcinoma , successfully treat squamous cell carcinoma skin situ carcinoma cervix treat cone biopsy . Previous history major psychiatric disorder require hospitalization current psychiatric disorder would impede patient 's ability provide inform consent comply protocol . Corticosteroids unless use substitutive therapy injection paclitaxel . Past history severe allergic episode and/or Quincke edema . Past present history organic disorder likely modify absorption , distribution elimination study drug . Alcohol substance abuse disorder . Radiotherapy within 30 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>IMP321</keyword>
	<keyword>hLAG-3Ig</keyword>
	<keyword>LAG-3</keyword>
	<keyword>CD223</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Combination therapy</keyword>
</DOC>